Bioven

**Bioven** is a human normal immunoglobulin for intravenous administration (IVIG), containing at least 98% immunoglobulin G (IgG), formulated as a 5% or 10% infusion solution with glycine and water for injection. It is indicated for replacement immunotherapy in primary immunodeficiency syndromes (e.g., congenital agammaglobulinemia, hypogammaglobulinemia, severe combined immunodeficiency, Wiskott-Aldrich syndrome) and secondary immunodeficiencies (e.g., cytopenias from leukemia or chemotherapy, severe bacterial/viral infections, post-bone marrow transplant). Additional uses include autoimmune diseases such as idiopathic thrombocytopenic purpura, Guillain-Barré syndrome, Kawasaki syndrome, and as adjunctive therapy for severe COVID-19 pneumonia. Developed and manufactured in Ukraine by Biopharma Plasma, it provides broad polyclonal antibodies to support immune function in patients with antibody deficiencies or acute infections.

Brand names

BiovenBioven Mono

Other names

Human normal immunoglobulinIVIGBioven 10%